摘要
目的 分析阿托伐他汀联合胞磷胆碱治疗脑小血管病(CSVD)轻度认知障碍(MCI)的疗效及对患者血-脑屏障功能和炎症因子的影响。方法 选取2021-03—2023-03自贡市第四人民医院收治的102例CSVD合并MCI患者为研究对象,分为观察组与对照组各51例。对照组口服胞磷胆碱钠片,观察组在对照组基础上加用阿托伐他汀钙片口服,2组均持续治疗3个月。治疗结束后比较2组患者临床疗效,以及治疗前、治疗3个月后蒙特利尔评定量表(MoCA)评分、血-脑屏障功能、炎症因子水平[血清C反应蛋白(CRP)、白细胞介素-6(IL-6)]和血脂水平[总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白(LDL-C)],记录治疗期间不良反应。结果 治疗后观察组总有效率优于对照组(94.12%比78.43%,P<0.05)。2组患者MoCA评分较治疗前均显著升高,观察组为(27.07±1.05)分,高于对照组的(25.89±1.54)分(P<0.05)。2组患者治疗后伊文思蓝水平、血清CRP、IL-6水平、血清TC、TG和LDL-C水平较治疗前均降低,观察组分别为(10.29±1.17)μg/g、(4.67±1.03)mg/L、(101.76±10.54)ng/L、(2.06±0.46)mmol/L、(1.65±0.32)mmol/L、(1.84±0.30)mmol/L,均低于对照组的(13.87±1.56)μg/g、(6.93±1.78)mg/L、(109.34±11.12)ng/L、(3.24±0.49)mmol/L、(2.24±0.48)mmol/L、(2.39±0.46)mmol/L(P<0.05)。2组患者治疗期间相关不良反应发生率无统计学差异(7.84%比5.88%,P>0.05)。结论 阿托伐他汀联合胞磷胆碱治疗CSVD合并MCI疗效确切,有利于改善患者认知功能、血-脑屏障功能,并降低炎症因子和脂质代谢水平。
Objective To analyze the curative effect of atorvastatin combined with citicoline in the treatment of patients with cerebral small vascular disease(CSVD)and mild cognitive impairment(MCI)and its influence on blood-brain barrier function and inflammatory factors.Methods A total of 102 patients with CSVD and MCI in the Fourth People’s Hospital of Zigong were enrolled as the research objects between March 2021 and March 2023.According to random number table method,they were divided into observation group and control group,51 cases in each group.The control group was given oral citicoline sodium tablets,while observation group was additionally given oral atorvastatin calcium tablets for 3 months.The clinical curative effect after treatment,scores of Montreal cognitive assessment(MoCA),blood-brain barrier function,the levels of inflammatory factors(serum C-reactive protein(CRP),interleukin-6(IL-6))and blood lipid indexes(total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C))before and after 3 months of treatment in the two groups were compared.The adverse reactions during treatment were recorded.Results After treatment,total response rate in observation group was better than that in control group(94.12%vs 78.43%,P<0.05).After treatment,MoCA scores in both groups were increased,which were higher in observation group than those of control group((27.07±1.05)points vs(25.89±1.54)points,P<0.05),while the levels of Evans blue,serum CRP,IL-6,TC,TG and LDL-C were decreased,which were lower in observation group than those of control group((10.29±1.17)μg/g,(4.67±1.03)mg/L,(101.76±10.54)ng/L,(2.06±0.46)mmol/L,(1.65±0.32)mmol/L,(1.84±0.30)mmol/L vs(13.87±1.56)μg/g,(6.93±1.78)mg/L,(109.34±11.12)ng/L,(3.24±0.49)mmol/L,(2.24±0.48)mmol/L,(2.39±0.46)mmol/L,P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups during treatment(7.84%vs 5.88%,P>0.05).Conclusion Curative effect of atorvastatin combined with citicoline is significant on patients with CSVD and MCI,which is beneficial to improve cognitive function and blood-brain barrier function,and reduce the levels of inflammatory factors and lipid metabolism.
作者
邓琳
丁昊
辜忠灵
DENG Lin;DING Hao;GU Zhongling(Zigong Fourth People’s Hospital,Zigong 643000,China)
出处
《中国实用神经疾病杂志》
2024年第4期473-477,共5页
Chinese Journal of Practical Nervous Diseases
基金
2019年四川省医学(青年创新)科研课题(编号:S19036)。
关键词
脑小血管病轻度认知障碍
阿托伐他汀
胞磷胆碱
血-脑屏障功能
炎症因子
Cerebral small vascular disease combined with mild cognitive impairment
Atorvastatin
Citicoline
Blood-brain barrier function
Inflammatory factor
